# Are growth hormone peptides legal? What regulators say

> One is an approved medicine for a single use, two are not approved anywhere checked. What FDA, EMA and the TGA have published about each.

Source page: https://peptioresearch.com/articles/are-growth-hormone-peptides-legal/
Publisher: Peptio Research. Educational summary of published research, not medical advice.
Last checked against its sources: 2026-10-06
Type: Safety

"Legal" is a question of national law, and this page does not answer it for any country. With one second-hand exception, set out below for Australia, none of the documents behind it addresses whether a person may buy, import or hold these peptides. What they do settle is narrower and more useful: whether a regulator has approved each one, what FDA has said about compounding it, and how FDA treats products sold under "research" labels. For the three growth hormone secretagogues this site covers, the answers differ sharply.

Tesamorelin is an approved medicine in the United States, for one use. Ipamorelin and CJC-1295 are not approved by any regulator checked for this page.

## Tesamorelin: approved, for one use

FDA approved tesamorelin on 10 November 2010, as Egrifta [1]. Its current label gives a single indication: the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy [2]. The label adds that it is not indicated for weight loss management [2]. An approval covers a medicine for its approved use; it is not an approval of the molecule for anything else.

In the EU it is not approved. The applicant withdrew its application on 21 June 2012, at a point when EMA's committee held the provisional opinion that it could not have been approved [3].

Products sold as tesamorelin outside that system are a different matter. In warning letters dated 24 August 2026, FDA named products sold as tesamorelin, in one case a "Tesamorelin Ipamorelin Blend", as unapproved new drugs [4] [5] [6]. The approval of Egrifta does not extend to them.

## Ipamorelin and CJC-1295: not approved

FDA states that neither ipamorelin nor CJC-1295 is a component of an FDA-approved drug [7] [8]. FDA's CJC-1295 briefing adds that there are no approved products containing any form of CJC-1295 in Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Japan, Norway, Spain or the United Kingdom [8]. Neither has an entry in the register of medicines EMA has assessed, in the copy generated on 2 October 2026; that register covers medicines assessed centrally, not authorisations by a single member state's agency [9].

In Australia, a joint statement of 19 June 2026 by the TGA and the Chief Medical Officer names CJC-1295 among unapproved peptide products that are not in the Australian Register of Therapeutic Goods and have not been evaluated by the TGA for safety, quality or effectiveness, and says unapproved peptide products have been added as a priority focus for TGA compliance [10]. A separate TGA safety advisory of 14 September 2026, about a counterfeit product sold as retatrutide, states as a general rule that the supply and advertising of unapproved therapeutic goods in Australia "is prohibited unless a relevant exemption applies" [11]. That rule concerns supply and advertising, not buying or possession, and none of the sources here sets out what the exemptions are. Both documents were read in a browser by a person on 4 October 2026, because the TGA's website could not be reached from the environment used to research this page [10] [11]. Ipamorelin is not named in either. FDA's 2024 briefing reports, citing a TGA scheduling decision of February 2016, that Australia's Advisory Committee on Medicines Scheduling recommended and confirmed adding ipamorelin to the Poisons Standard, among performance and image enhancing drugs for which possession without authority is illegal, for example possession other than in accordance with a legal prescription [7]. That is FDA's second-hand account of an Australian decision; the TGA's own document could not be opened for this page.

## Compounding in the United States

Under section 503A, for a compounded drug to qualify for the section's exemptions, a bulk substance used by a state-licensed pharmacy must meet an applicable USP or NF monograph; if none exists, be a component of an approved drug; and if it is neither, appear on FDA's 503A bulks list [12]. FDA states that ipamorelin has no applicable monograph and is not a component of an approved drug, and the same for every form of CJC-1295 [7] [8], which leaves the list. Both were nominated for it, and in 2024 FDA proposed not adding either [7] [8]. Asked whether each should be placed on the list, its advisory committee voted 0 yes, 12 no and 1 abstaining for each form of ipamorelin [13], and 0 yes and 13 no for four forms of CJC-1295, with 1 yes and 12 no for CJC-1295 acetate [14]. Neither appears in any category of FDA's 503A list updated 14 May 2026 [15].

FDA's page on bulk drug substances that may present significant safety risks, current as of 22 April 2026, places ipamorelin acetate in Category 2 under the interim policy for outsourcing facilities (section 503B). It also lists CJC-1295 and ipamorelin acetate among substances previously in Category 2 whose nominations were withdrawn by their nominators [16]. FDA's CJC-1295 briefing notes that the nominations it reviewed had been withdrawn and that FDA was evaluating the substances at its discretion [8].

> **Key point.**
> The documents read for this page record FDA's proposals, its advisory committee's votes and its current lists. They do not show a final FDA determination on either compound under section 503A [7] [8] [15]. Neither is in Category 1 of the 503A list, "Bulk Drug Substances Under Evaluation" [15]. For outsourcing facilities, an FDA warning letter describes appearing in the corresponding 503B Category 1 as one of the conditions of FDA's interim policy [12], and ipamorelin acetate is in 503B Category 2 instead [16].

## "For research use only"

Many of these products are sold with labels saying they are for research, or not for human consumption. FDA does not treat that label as decisive. In the August 2026 letters, it wrote, for example, that despite statements on the labelling marketing the products "for laboratory, research, and analytical use" and "not intended for human or veterinary use," evidence obtained from the seller's website established that the products were intended to be drugs for human use [4]. The other two letters cited here, of the same date, make the same finding [5] [6].

## Sport

The World Anti-Doping Agency's Prohibited List names all three under S2.2.4, growth hormone releasing factors, prohibited at all times: ipamorelin among growth hormone secretagogues, CJC-1295 and tesamorelin among growth hormone-releasing hormone analogues. The list was read in a browser by a person on 11 October 2026, because WADA's site refuses automated clients [17]. Earlier second-hand accounts agree: FDA's 2024 briefing on ipamorelin says it is on WADA's list under section S2.4, citing the 2023 list [7]; FDA's briefing on CJC-1295, citing the list as accessed in April 2024, says growth hormone secretagogues including CJC-1295 are prohibited at all times [8]; and a 2022 anti-doping laboratory paper describes tesamorelin among the prohibited growth hormone-releasing hormone analogues it was built to detect [18].

## What the evidence for each one is

Approval and evidence are separate questions. The [tesamorelin](/peptides/tesamorelin/), [ipamorelin](/peptides/ipamorelin/) and [CJC-1295](/peptides/cjc-1295/) pages set out what has been measured in people for each, and the [comparison of CJC-1295 and ipamorelin](/articles/cjc-1295-vs-ipamorelin/) sets those two side by side.

## Sources

1. NDA 022505 approval letter, Egrifta (tesamorelin for injection), November 10, 2010. U.S. Food and Drug Administration. 2010. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022505s000ltr.pdf
2. EGRIFTA WR (tesamorelin) for injection. Prescribing Information, revised 3/2025 (application 022505). U.S. Food and Drug Administration, Drugs@FDA. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
3. Questions and answers: Withdrawal of the marketing authorisation application for Egrifta (tesamorelin), 12 July 2012 (EMA/CHMP/475021/2012). European Medicines Agency. 2012. https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_en.pdf
4. FDA Warning Letter, MARCS-CMS 733652, August 24, 2026. U.S. Food and Drug Administration. 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026
5. FDA Warning Letter, MARCS-CMS 735063, August 24, 2026. U.S. Food and Drug Administration. 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026
6. FDA Warning Letter, MARCS-CMS 735067, August 24, 2026. U.S. Food and Drug Administration. 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/txp-innovations-llc-dba-tex-peptides-735067-08242026
7. FDA Briefing Document, Pharmacy Compounding Advisory Committee, October 29, 2024: Ipamorelin-Related Bulk Drug Substances (Ipamorelin (free base) and Ipamorelin Acetate). U.S. Food and Drug Administration. 2024. https://www.fda.gov/media/182088/download
8. FDA Briefing Document, Pharmacy Compounding Advisory Committee, December 4, 2024: CJC-1295-Related Bulk Drug Substances. U.S. Food and Drug Administration. 2024. https://www.fda.gov/media/183819/download
9. Medicines output: medicines report (generated 2 October 2026). European Medicines Agency. 2026. https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx
10. Concerns regarding the public health risks associated with unapproved peptide products. Therapeutic Goods Administration. 2026. https://www.tga.gov.au/news/media-releases/concerns-regarding-public-health-risks-associated-unapproved-peptide-products
11. TGA tests counterfeit retatrutide product following serious adverse event report. Therapeutic Goods Administration. 2026. https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/tga-tests-counterfeit-retatrutide-product-following-serious-adverse-event-report
12. FDA Warning Letter, MARCS-CMS 715883, September 9, 2025. U.S. Food and Drug Administration. 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025
13. Pharmacy Compounding Advisory Committee, October 29, 2024: Final Summary Minutes. U.S. Food and Drug Administration. 2024. https://www.fda.gov/media/185412/download
14. Pharmacy Compounding Advisory Committee, December 4, 2024: Final Summary Minutes. U.S. Food and Drug Administration. 2025. https://www.fda.gov/media/185642/download
15. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, updated May 14, 2026. U.S. Food and Drug Administration. 2026. https://www.fda.gov/media/94155/download
16. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
17. The Prohibited List, World Anti-Doping Agency. World Anti-Doping Agency. 2026. https://www.wada-ama.org/en/prohibited-list
18. Coppieters G et al. An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.. Journal of Pharmaceutical and Biomedical Analysis. 2022. https://doi.org/10.1016/j.jpba.2022.114726
